DailyIQ
Last updated1 minute ago

ALGN·Align Technology, Inc.

$141.58
+0.93 (+0.66%)
After Hours
High
$143.64
Open
$141.96
Market Cap
10.10B
52W High
$200.44
Low
$139.61
P. Close
$141.58
P/E
24.42
52W Low
$124.24
Fwd P/E
11.27
DailyIQ Est.
$210.74
Inst. Ownership
51.8%
Short Interest
5.47%
Days to Cover
4.9
Technical Score (1D)
0
BEARISH
News Sentiment
39
BEARISH
On Oct 6, a Benzinga article noted that Align Technology (ALGN) was considered oversold, with its RSI near 30, and suggested the stock could offer a value opportunity for investors. The piece also mentioned Dianthus Therapeutics and Ocular Therapeutix as other oversold health‑care stocks, but did not cite any specific catalysts or earnings guidance for any of the companies. On Oct 5, Align Technology shares fell about 1.9% after Evercore ISI downgraded the stock to in‑line from outperform and lowered its price target from $220 to $155. The downgrade reflected a reassessment of the company’s valuation and growth prospects, and trading volume spiked to 1.2 million shares, well above the daily average. The Benzinga report focused on technical indicators, while the Evercore ISI downgrade highlighted a shift in analyst sentiment toward a more limited upside outlook for ALGN.
LOW TARGET
$170 +21.8%
2 analysts
MEAN TARGET
$206 +47.8%
13 analysts
HIGH TARGET
$235 +68.3%
11 analysts
PRICE RANGE
$170.00 - $235.00
SB / B / H / S / SS
7/9/8/1/1
DAILYIQ EST.
$210.74 (+50.9%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NMS
Country
United States
Symbol
ALGN
Description
Align Technology is a global medical device company specializing in digital dentistry solutions. Its core business revolves around the design, manufacture, and marketing of the Invisalign system, a leading brand of clear aligners used to straighten teeth for both adults and teenagers. Align also offers Vivera retainers, designed to maintain the results achieved with Invisalign treatment, and iTero intraoral scanners, which provide digital impressions for various dental procedures. These scanners are integral to the company's value proposition, enabling precise treatment planning and digital workflows for orthodontists and dentists. Operating internationally, Align Technology competes in the dental and orthodontic markets with a focus on innovative technology and digital solutions.
Bought (1Y)
0 shares
$0
Sold (1Y)
0 shares
$0
Blackford Quentin S.-
Award/Grant1,376 shares2026-08-27
MORROW GEORGE J-
Option Exercise1,745 shares2026-05-20
MORROW GEORGE J-
Option Exercise1,745 shares2026-05-20
Conroy Kevin T-
Award/Grant1,836 shares2026-05-20
Conroy Kevin T-
Option Exercise1,745 shares2026-05-20
76/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.2%
Net Margin
10.2%
Revenue CAGR
16.4%
Current Ratio
1.36x
Return on Equity
10.1%
Earnings Summary
Align Technology is a global medical device company specializing in digital dentistry solutions, primarily the Invisalign clear aligner system, Vivera retainers, and iTero intraoral scanners that enable precise treatment planning for orthodontists and dentists. The company operates internationally within the medical instruments and supplies sector, competing on innovation and digital workflows. In the most recent two quarters, Q4 2025 and Q1 2026, Align reported EPS of $3.29 and $2.58 respectively, both beating estimates of $3.03 and $2.33, while revenue remained flat at $1.0476 bn and $1.0401 bn, slightly below the $1.0537 bn and $1.0421 bn estimates; the company has consistently delivered EPS beats in the last four quarters, though revenue has trended lower than guidance. Historically, Align’s YoY revenue growth has been modest, expanding at only about 2.5 % per year, and EPS growth over five years has lagged peers at 1.4 %, indicating a consistent pattern of solid profitability but restrained top‑line momentum. Recent news highlights a valuation discussion, with analysts noting the company’s debt‑free balance sheet and modest growth prospects; a forthcoming earnings release on Oct. 28, 2026 will be closely watched for guidance on revenue and margin, as any flat or weak outlook could tighten upside.

EPS

EstBeatMiss
$2.18$2.49$2.81$3.12$3.43Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.79 - -
Q2'26$2.66$2.64-0.9%
Q1'26$2.33$2.58+11.0%
Q4'25$3.03$3.29+8.5%
Q3'25$2.41$2.61+8.4%
Q2'25$2.57$2.49-3.3%

Revenue

EstBeatMiss
$984M$1.0B$1.0B$1.1B$1.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.0B - -
Q2'26$1.1B$1.1B-1.6%
Q1'26$1.0B$1.0B-0.2%
Q4'25$1.1B$1.0B-0.6%
Q3'25 - $996M -
Q2'25 - $1.0B -

Market Data

ALGN Stock Snapshot

BEARISH0/100
$139.61−$1.97 (1.4%)
Market cap
10.10B
P/E ratio
24.4
Day range
$139.61 – $143.64
News sentiment
39/100 · Bearish
Analyst target
$206.36 (+47.8%)
Consensus
Buy · 26 analysts
52-week range+12.4% off low · -30.3% from high
$124.24$200.44
Price $139.61 DailyIQ Est. $210.74

Momentum has rolled over on Align Technology, Inc., which is what drives the bearish read. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Behaviour On Record

What ALGN's own history says about today's numbers

Realized volatility (21d)
30.5% 35th pct
Below its peak
-80.7%
vs 200-day average
-17.5%
Up days (1y)
49%

Align Technology, Inc. is currently running 30.5% annualised volatility over the last 21 sessions. Measured against ALGN's own 13 years of daily returns rather than a market-wide average, that is the 35th percentile — on the quiet side for this stock, against a typical reading of 36.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ALGN is trading -80.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -42.5%, and the deepest was -72.9% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -17.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 19th percentile — a narrower gap than it typically runs. Over the past year ALGN closed higher on 49% of sessions, and it is currently 3 sessions into a falling streak.

On October specifically: over 13 years of records, ALGN finished the month higher 7 of 13 times, with a median return of +5.1% and an average of +2.9%. Its strongest month historically has been November at +5.2% on average, its weakest September at -2.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ALGN has opened more than 2% away from the prior close in 194 of 3,265 sessions (5.9% of the time), with the largest gaps running +10.3% and -11.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ALGN moved an average of 3.0% in the session after earnings, closing higher 1 of those 3 times, with a median move of -2.2% and a largest of -4.0%.

All figures computed from 3,266 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ALGN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ALGN's sector?

Align Technology, Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for ALGN?

CallsPuts

For Align Technology, Inc.'s nearest expiry (2026-10-09, 3 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.76), with at-the-money implied volatility around 89.0%. The options market is pricing roughly a ±9.2% move by that expiry — a range of about $134.37–$161.63.

Put/call ratio (2026-10-09)
1.76
ATM implied volatility
89.0%
Total open interest
1,458
Expected move by 2026-10-09
±9.2% ($134.37–$161.63)

Analyst Rating Changes

Are analysts turning bullish or bearish on ALGN?

Evercore ISI Group most recently downgraded Align Technology, Inc. to In-Line on Oct 5, 2026 with a price target of $155 (from $220). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Evercore ISI Group — In-Line
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 5, 2026Evercore ISI GroupDowngradeOutperform → In-Line$220 → $155
Jul 23, 2026UBSMaintainedNeutral$186 → $189
Jul 9, 2026BMO CapitalInitiatedOutperform$209
Apr 30, 2026Evercore ISI GroupMaintainedOutperform$200 → $220
Apr 30, 2026MizuhoMaintainedOutperform$215 → $220
Apr 24, 2026Morgan StanleyMaintainedEqual-Weight$169 → $188
Apr 21, 2026Piper SandlerMaintainedOverweight$220 → $235
Apr 15, 2026CitigroupInitiatedBuy$240
Mar 17, 2026BarclaysUpgradeEqual-Weight → Overweight$200
Feb 26, 2026BarclaysMaintainedEqual-Weight$170 → $200
Feb 9, 2026HSBCUpgradeHold → Buy$150 → $200
Feb 5, 2026StifelMaintainedBuy$200 → $210

ALGN Competitive Positioning

Align Technology, Inc. (ALGN) is tracked alongside these names in Medical Instruments & Supplies on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

39/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The Benzinga article highlighted three health care stocks—Align Technology (ALGN), Dianthus Therapeutics, and Ocular Therapeutix—as oversold based on RSI readings near or below 30. It suggested that these stocks could present value opportunities for investors seeking potential upside. No specific catalysts or earnings guidance were mentioned, and the piece did not indicate any imminent corporate events. The focus remained on technical indicators rather than fundamental developments. Consequently, the article implied a mild, non-material headwind for the sector without concrete upside drivers.
What did this article say?
Align Technology (ALGN) shares fell roughly 1.9% on Monday after Evercore ISI downgraded the stock to in‑line from outperform and reduced its price target to $155 from $220. The downgrade reflected a reassessment of the company’s valuation and growth prospects. Trading volume exceeded 1.2 million shares, well above the daily average of about 891,000, indicating heightened investor activity around the news. The move signals a modest negative sentiment for ALGN, as analysts now view the company’s upside potential as more limited.
What did this article say?
Evercore ISI downgraded Align Technology (ALGN) from Outperform to In‑Line and lowered its price target from $220 to $155. The move follows a review of the company’s recent financials and outlook. The downgrade signals a more cautious view of ALGN’s near‑term growth prospects. Investors reacted with a modest pre‑market decline in the stock. The rating change reflects analysts’ concerns about margin pressure and competitive dynamics in the clear‑aligner market.
What did this article say?
Evercore ISI downgraded Align Technology (ALGN) from Outperform to In‑Line, prompting a 1.7% decline in pre‑market trading on October 5. The downgrade precedes ALGN’s third‑quarter 2026 earnings release scheduled for October 28. Despite record Clear Aligner revenue of $870.9 million in Q2, Systems and Services revenue fell 10.8% due to a shift toward lower‑priced scanners and leasing models. Management maintained a third‑quarter revenue outlook of $1.0‑$1.02 billion and full‑year growth of 3‑4%, while expanding its share‑repurchase program to $400‑$500 million.
What did this article say?
Evercore ISI reduced its recommendation for Align Technology (ALGN) from outperform to in‑line, signaling a more cautious view of the company’s near‑term prospects. The downgrade reflects concerns about the firm’s valuation relative to peers and the potential slowdown in its flagship product demand. The rating change does not alter the average overweight stance or the mean price target of $207.23. The move may influence investor sentiment but is not expected to cause a significant market shift.
What did this article say?
An analyst at HubSpot announced a downgrade of Align Technology, reducing its rating and price target. The decision followed broader market concerns over the company's growth prospects. The downgrade reflects a cautious view on Align’s future earnings potential. The move may influence investor sentiment and trading activity for the stock.
What did this article say?
Evercore ISI Group analyst Elizabeth Anderson downgraded Align Technology (NASDAQ:ALGN) from Outperform to In‑Line. The firm reduced its price target from $220 to $155, citing concerns over earnings growth and competitive pressure. The downgrade signals a negative outlook for ALGN’s near‑term valuation and may influence investor sentiment.
What did this article say?
Align Technology’s stock has dropped nearly 78% over the past five years, prompting investors to reassess whether current earnings justify the price. Analysts have examined the company’s performance relative to the broader dental equipment sector, noting potential upside from digital tools such as intraoral scanners and 3D printing. The article compares Align’s valuation multiples to peers, suggesting the share price may be supported by future demand trends. No material corporate action or earnings surprise is reported, leaving the outlook largely unchanged.
What did this article say?
Align Technology announced its third‑quarter 2026 earnings release will occur on October 28, following a 6% share price decline over the past month and a 21% drop over the last quarter. The company’s 12.9% one‑year total shareholder return contrasts with weaker multi‑year performance, indicating short‑term momentum has faded. The announcement provides a clear timeline for investors but does not signal any material change to guidance or contracts.
What did this article say?
Align Technology (ALGN) has consistently outperformed earnings estimates, with the most recent quarter reporting $2.64 per share versus a $2.56 consensus, a 3.13% surprise. The company’s historical average surprise over the past two quarters was 8.64%, and the previous quarter saw a 14.16% beat. Analysts note that expectations are rising, and the Zacks Expected Surprise Prediction remains positive, reinforcing confidence in another earnings beat. This track record supports a bullish view for the upcoming earnings announcement.

Technical Analysis

Real-time indicators across multiple timeframes

0
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.01B combined position · 15 adding, 9 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell8,179,77911.47%$1.28B2026-01-29
BlackRock, Inc.▲ Buy4,419,3666.20%$745.37M2026-08-07
FMR LLC (Fidelity)▲ Buy4,060,0325.69%$684.77M2026-08-13
Capital World Investors▼ Sell3,422,3854.80%$577.22M2026-08-12
Goldman Sachs Group Inc▲ Buy3,388,7604.75%$571.55M2026-08-14
Geode Capital Management, LLC▲ Buy2,245,3153.15%$378.15M2026-08-12
Invesco Ltd.▲ Buy1,413,5671.98%$238.41M2026-08-14
Ruane, Cunniff & Goldfarb L.P.▼ Sell1,171,4551.64%$197.58M2026-08-14
Morgan Stanley▲ Buy1,013,8421.42%$170.99M2026-08-13
Norges Bank▼ Sell904,6231.27%$152.57M2026-08-12
AQR Capital Management LLC▲ Buy899,7311.26%$151.16M2026-08-14
Susquehanna International Group, LLP▼ Sell871,8251.22%$147.04M2026-08-14
JPMorgan Chase & Co▲ Buy773,1821.08%$134.65M2026-08-12
Northern Trust Corp▼ Sell562,2410.79%$94.83M2026-08-13
Bank of America Corp▲ Buy551,9120.77%$93.09M2026-08-14
Citadel Advisors LLC• Hold513,6820.72%$86.64M2026-09-02
Bares Capital Management, Inc.▲ Buy609,7220.86%$76.35M2025-11-14
Wells Fargo & Company▼ Sell280,1450.39%$47.25M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy215,9420.30%$36.42M2026-08-14
AllianceBernstein L.P.▼ Sell210,1810.29%$36.03M2026-08-14
Gotham Asset Management, LLC▲ Buy185,9540.26%$31.36M2026-08-14
Citigroup Inc▲ Buy142,6040.20%$24.05M2026-08-03
Artisan Partners Limited Partnership▼ Sell139,3330.20%$23.50M2026-08-13
Adage Capital Partners GP, L.L.C.▲ Buy130,3140.18%$22.34M2026-05-15
Bridgewater Associates, LP▲ Buy82,4000.12%$13.90M2026-08-14
Q2 2026 flow:3.97M sh bought ($670.38M)1.08M sh sold ($182.75M)net +2.89M sh (+$487.62M)
Congressional Trading Activity
9 disclosed trades · ~$72.0K est. traded value · 4 buys, 5 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-09-112025-10-22
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-08-042025-09-12
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-02-262025-03-06
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Dan SullivanSenateAK▼ Sell$1K - $15K2023-08-222023-09-22
Dan SullivanSenateAK▲ Buy$1K - $15K2023-01-102023-02-13
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-10-052022-11-10
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23